KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Clinical efficacy and multi-omics analysis of Si-Ni-San for depression treatment in breast cancer patients: a randomized, double-blind, placebo-controlled, crossover trial. PMID 41491244 · Chin Med · 2026-Jan-06 The study is a randomized, double-blind, placebo-controlled trial in breast cancer patients, but it evaluates a Traditional Chinese Medicine formula for depression symptoms, not a pharmaceutical drug for oncological efficacy. The primary endpoint is a depression scale score, not a time-to-event endpoint such as OS, PFS, or DFS. No Kaplan-Meier or HR data are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer. PMID 41213103 · Clin Cancer Res · 2026-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial. PMID 41128656 · Clin Cancer Res · 2026-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial. PMID 40833744 · Clin Cancer Res · 2026-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Economic Evaluation of Tobacco Treatments From the Screen ASSIST Lung Cancer Screening Trial. PMID 41575745 · JAMA Netw Open · 2026-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of secukinumab with modified nourishing blood and moisturising decoction on superficial fungal infections in patients with psoriasis with blood-dryness pattern. PMID 41528783 · J Wound Care · 2026-Jan-02 The study evaluates a drug intervention in a randomized trial for psoriasis, which is not an oncologic malignancy. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. PMID 40774695 · J Nucl Med · 2026-Jan-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A prospective randomized study of sequential boost versus simultaneous integrated boost intensity-modulated radiation therapy with concurrent chemotherapy in locally advanced head and neck cancer. PMID 41910297 · J Cancer Res Ther · 2026-Jan-01 While the trial meets most criteria (oncology, human, randomized, time-to-event, drug intervention, original results), the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. Eligibility requires explicit establishment of all criteria, including trial phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). PMID 41524552 · Endocr Relat Cancer · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Anesthesia Type during Cancer Surgery: Results of the GA-CARES Randomized, Multicenter Trial. PMID 41363871 · Anesthesiology · 2026-Jan-01 The study is an oncology randomized trial with a time-to-event primary endpoint (all-cause mortality) and is an original result report. However, the intervention is a type of general anesthesia (propofol vs. volatile agent) used during cancer surgery, not a systemic or targeted drug therapy for the cancer itself. The drug intervention criterion requires a drug-containing cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy). Anesthesia choice is a perioperative supportive care intervention, not a cancer-directed drug intervention. Phase III status is not explicitly stated in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer: The UMC-UPPERGI-01 Randomized Clinical Trial. PMID 41222957 · JAMA Surg · 2026-Jan-01 The record is a randomized trial in oncology with original results, but it is excluded because it does not meet the required Phase (likely Phase II, not explicitly Phase III/IIIb or Phase II/III), does not have a time-to-event efficacy endpoint (focus is on short-term surgical outcomes), and does not involve a drug-containing intervention (surgical procedures only).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. PMID 41205202 · JAMA Cardiol · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study. PMID 41021893 · Clin Nucl Med · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis. PMID 40997114 · Inflamm Bowel Dis · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of intraoperative low-dose esketamine on postoperative quality of recovery in patients undergoing laparotomy for gynecologic malignancy: a randomized controlled trial. PMID 40990647 · Int J Surg · 2026-Jan-01 While the study is a randomized, oncology drug trial with original results, it does not meet the required primary/key secondary time-to-event efficacy endpoint criterion (OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier/HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of D3 lymph node dissection extent on postoperative bowel function and nutritional status in right-sided colon cancer: a prospective randomized controlled trial. PMID 40928287 · Int J Surg · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of Resistance versus High-Intensity Interval Training on Myokines and Cancer Cell Suppression in Breast Cancer Survivors: A Randomized Trial. PMID 40903011 · Med Sci Sports Exerc · 2026-Jan-01 The study is a randomized trial in oncology but fails on multiple required criteria: no drug intervention, no specified definitive phase, and no time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. PMID 40876501 · Cancer Lett · 2026-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016. PMID 40829719 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 This is a secondary analysis of a Phase III randomized trial in oncology with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoint is a patient-reported outcome (hearing handicap).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion. PMID 40818045 · Int J Cancer · 2026-Jan-01 The study is a randomized, controlled, human oncology trial with a drug intervention and primary time-to-event endpoint (OS). However, it is not explicitly identified as a Phase III or Phase II/III trial. The abstract and metadata do not specify the trial phase. Per the adjudication rules, the phase must be explicitly established to be eligible; it cannot be inferred. Therefore, it does not meet the 'phase3_or_definitive' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results. PMID 40780546 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 The report is an original result from a randomized Phase III oncology trial in humans, but the intervention is radiation therapy without a drug component, and the primary endpoint reported is acute toxicity, not a time-to-event efficacy outcome like OS, PFS, DFS, EFS, RFS, TTP, or its associated Kaplan-Meier/HR analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized, double-blind phase III trial of a dexamethasone-free regimen for managing highly emetogenic chemotherapy-induced nausea and vomiting. PMID 40735921 · Int J Cancer · 2026-Jan-01 The trial is a randomized, phase III oncology study with drug interventions, but its primary endpoint is a categorical response rate (complete response), not a time-to-event endpoint such as OS, PFS, or DFS. There is no mention of Kaplan-Meier analysis or hazard ratios.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH). PMID 40609842 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative study of Chinese herbal enema combined with mesalazine vs mesalazine alone in the treatment of ulcerative colitis: A randomized controlled trial. PMID 40533886 · J Chin Med Assoc · 2026-Jan-01 The study is a randomized controlled trial with a drug intervention (mesalazine) and reports primary efficacy results. However, it is excluded because it is not an oncology study (focus on ulcerative colitis) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. PMID 42395839 · Endocr Oncol · 2026-Jan The record describes a Phase III randomized controlled trial in oncology with a drug intervention and original results, but the primary endpoint is a change in biomarkers associated with metabolic syndrome, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier survival curves or hazard ratios are reported or implied.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Prospective Study Comparing Treatment Outcomes of Brentuximab Vedotin Plus AVD versus ABVD in Egyptian Patients with Advanced Classical Hodgkin Lymphoma. PMID 42274064 · Gulf J Oncolog · 2026-Jan The record describes a randomized, prospective, open-label study comparing a drug-containing regimen (Brentuximab Vedotin + AVD) vs. ABVD in advanced Hodgkin lymphoma, with a primary time-to-event endpoint (PFS). It is an original report of results. However, the title, abstract, and metadata do not explicitly state the trial phase (e.g., Phase III). The deterministic review flagged 'phase3_evidence_unclear'. The inclusion criterion requires the phase to be explicitly established as Phase III/IIIb or Phase II/III, which is not present here. Therefore, is_eligible is set to false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Breast cancer: an example of changing practices that take age-related factors into account. About the ASTER 70s study]. PMID 41729638 · Rev Prat · 2026-Jan The record describes a Phase III randomized trial in oncology (breast cancer) with a drug intervention (adjuvant chemotherapy) and is a primary result report. However, the abstract does not explicitly mention a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. The deterministic review correctly identified the absence of a time-to-event signal, making eligibility uncertain. Without explicit confirmation of a time-to-event endpoint, the record cannot be deemed eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial. PMID 41713468 · Lancet Healthy Longev · 2026-Jan The study is a randomized, open-label, non-inferiority trial in frail older patients with head and neck squamous-cell carcinoma. It reports a primary efficacy endpoint (6-month complete locoregional response rate) and a key secondary time-to-event endpoint (overall survival with HR). However, the intervention consists solely of two different radiotherapy fractionation schedules (standard vs. hypofractionated split-course). There is no drug-containing intervention (e.g., chemotherapy, targeted therapy, immunotherapy). Therefore, it does not meet the criterion of a drug-containing intervention required for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial. PMID 41686056 · Curr Med Res Opin · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Association between statin use and risk of incident cancer in healthy older adults: a target trial emulation using data from a multicentre, randomised trial of community-dwelling older adults in Australia and the USA. PMID 41583365 · EClinicalMedicine · 2026-Jan The record is an observational target trial emulation analyzing statin use as an exposure, not a randomized trial of a drug intervention. It does not meet the core criteria for being a randomized trial of a drug intervention in a defined phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimising the European Code Against Cancer, 5th edition, to increase awareness of avoidable cancer risks in all socioeconomic groups. PMID 41542812 · Mol Oncol · 2026-Jan The record is a randomized trial on cancer prevention awareness, but it does not meet key eligibility criteria: it lacks a drug intervention and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
AI-Enhanced Versus Clinician-Guided Expressive Writing for Improving Psychological Well-Being in Cancer Survivors: A Randomized Controlled Trial. PMID 41539978 · Psychooncology · 2026-Jan The study is an oncology randomized trial with human participants and original results, but it fails two key eligibility criteria: it does not involve a drug-containing intervention (it is a psychological/behavioral intervention) and it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer. PMID 41533999 · JCO Precis Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE). PMID 41514313 · J Gynecol Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. PMID 41513590 · Cancer Med · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. PMID 41502925 · EClinicalMedicine · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Feasibility of an early versus delayed rehabilitation intervention in patients with lung cancer on cancer-related fatigue: a pilot RCT. PMID 41496492 · Future Oncol · 2026-Jan This is a clinical trial protocol for a feasibility pilot RCT investigating a non-drug rehabilitation intervention for lung cancer patients. It does not meet the criteria for an original formal-result report with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study. PMID 41494223 · ESMO Open · 2026-Jan The record is excluded because it is a retrospective, observational real-world study, not an original, randomized Phase III/IIIb or Phase II/III trial. While it analyzes drug intervention (immunotherapy) and time-to-event endpoints (OS, PFS) in oncology, it fails the core eligibility criteria of being a randomized trial and having its own definitive trial phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tolerability and efficacy of an enteral formula containing partially hydrolyzed guar gum in patients following gastrointestinal surgery: A prospective, multicenter, open-label, randomized controlled study. PMID 41483486 · Clin Nutr · 2026-Jan The record is a randomized controlled trial but does not meet the core eligibility criteria for the oncology KM digitization cohort. It is not an oncology study, does not involve a drug intervention, and lacks a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Diet, body composition and metabolic and hormonal profile in women at high risk of breast cancer recurrence: A secondary mediation analysis of the DIANA-5 trial. PMID 41483481 · Clin Nutr · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic value of T-lymphocyte subsets, lymphocyte-to-high-density lipoprotein ratio, interleukin 6, C-reactive protein and procalcitonin in patients with septic shock and effects of vitamin C on patients with septic shock. PMID 41482786 · Pak J Pharm Sci · 2026-Jan The study is not in the field of oncology (it is about septic shock). It does not have a primary or key time-to-event efficacy endpoint (such as OS, PFS, etc.) as required for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer. PMID 41482527 · Nat Cancer · 2026-Jan Metadata clearly establishes all eligibility criteria except for a time-to-event efficacy endpoint (OS, PFS, DFS, etc., Kaplan-Meier, HR). The abstract and signals do not explicitly mention a specific time-to-event endpoint, so eligibility cannot be confirmed. Confidence is low due to this missing explicit signal.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial. PMID 41456496 · Leuk Res · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS. PMID 41450200 · Cancer Med · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial. PMID 41449791 · Int J Urol · 2026-Jan The study is a Phase III clinical trial in bladder cancer, but it is a single-arm (non-randomized) study evaluating adverse events of 5-ALA (a photosensitizing agent used for diagnostic guidance, not a therapeutic drug intervention) during TURBT. The analysis is focused on safety (incidence of gastrointestinal and hepatic adverse events) and predictive factors, not on time-to-event efficacy endpoints like OS, PFS, DFS, etc. It does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circadian and gut-brain axis modulation is associated with neuroimmune and symptom recovery after rectal cancer surgery: An exploratory randomized controlled trial. PMID 41418645 · Behav Res Ther · 2026-Jan The trial is not eligible because it does not meet the drug intervention criterion. The intervention is primarily a non-drug behavioral and circadian program, with melatonin as a single component, making it 'non-drug-only' per the exclusion criteria. Additionally, it is an exploratory trial, not a definitive Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30). PMID 41380977 · Radiother Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol. PMID 41377199 · Adv Radiat Oncol · 2026-Jan 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. PMID 41365312 · Lancet Haematol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Identifying Predictors of Recurrent Pilonidal Disease in Adolescents and Young Adults: A Secondary Analysis of a Randomized Controlled Trial. PMID 41365098 · J Surg Res · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -